McKesson Quarterly Report: September 2025 Financials

These sources consist of excerpts from McKesson Corporation's financial filings, likely a Quarterly Report on Form 10-Q, which details their financial performance, condition, and operational changes for periods ending on September 30, 2025. The documents provide a comprehensive overview of the company's business segments, including the newly structured North American Pharmaceutical and Oncology & Multispecialty divisions, along with disclosures about the planned separation of the Medical-Surgical Solutions segment and the sale of Norwegian operations. Key financial data is presented, such as revenues, diluted earnings per share, and cash flow changes, highlighting the impact of recent acquisitions like PRISM Vision and Core Ventures. Furthermore, the documents address significant litigation liabilities related to opioid settlements and discuss the company's reliance on both Generally Accepted Accounting Principles (GAAP) and various Non-GAAP financial measures.